Primary malignant lymphoma and multiple myeloma are not included
  • American Joint Committee on Cancer

Summary of Changes

T1 has changed from “Tumor confined within the cortex” to “Tumor 8 cm or less in greatest dimension.”

T2 has changed from “Tumor invades beyond the cortex” to “Tumor more than 8 cm in greatest dimension.”

T3 designation of skip metastasis is defined as “Discontinuous tumors in the primary bone site.” This designation is a Stage III tumor that was not previously defined.

M1 lesions have been divided into M1a and M1b.

M1a is lung-only metastases.

M1b is metastases to other distant sites, including lymph nodes.

In the Stage Grouping, Stage IVA is M1a, and Stage IVB is Mlb


Malignant Peripheral Nerve Sheath Tumor Lymphatic Vessel Invasion Mesenchymal Chondrosarcoma Myxoid Chondrosarcoma Primary Malignant Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bacci G, Ferrari S, Bertoni F, et al: Prognostic factors in non-metastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18:4–11, 2000PubMedGoogle Scholar
  2. Baldini M, Scotlani K, Barbanti-Brodano G, et al: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380–1385, 1995PubMedCrossRefGoogle Scholar
  3. Bieling P, Rehan N, Winkler P, et al: Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14(3): 848–858, 1996PubMedGoogle Scholar
  4. Cotterill SJ, Ahrens S, Paulussen M, et al: Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18:3108–3114, 2000PubMedGoogle Scholar
  5. Davis A, Bell R, Goodwin P: Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12(2):423–431, 1994PubMedGoogle Scholar
  6. de Alva E, Antonescu CR, Panizo A, et al: Prognostic impact of P53 status in Ewing sarcoma. Cancer; 89:783–792, 2000CrossRefGoogle Scholar
  7. de Alva E, Kawai A, Healey JH, et al: EWS-FL11 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol 16:1248–1255, 1998Google Scholar
  8. Enneking WF, Spanier S, Goodman M: A system for the surgical staging of musculoskeletal sarcoma. Clin Orth and Rel Research No. 153, 106–120, 1980Google Scholar
  9. Evans R, Nesbit M, Askin F, et al: Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with nonmetastatic Ewing’s sarcoma of the pelvic bones. Int J Radiat Oncol Biol Phys 11:129–136, 1985PubMedCrossRefGoogle Scholar
  10. Glasser DB, Lane JM, Huvos AG, et al: Survival, prognosis and therapeutic response in osteosarcoma: the Memorial Hospital experience. Cancer 67:698–708, 1992CrossRefGoogle Scholar
  11. Gorlick R, Hubos AG, Heller G, et al: Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17:2781–2788, 1999PubMedGoogle Scholar
  12. Hornicek FJ, Gebhardt MC, Wolfe M, et al: P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop and Rel Research 373:11–17, 2000CrossRefGoogle Scholar
  13. Mankin HJ, Mankin CJ, Simon MA: The hazards of biopsy, revisited. J Bone and Joint Surg 78A:659–663, 1996Google Scholar
  14. Peabody TD, Gibbs CP, Simon MA: Evaluation and staging of musculoskeletal neoplasms. J Bone and Joint Surg 80A: 1204–1218, 1998Google Scholar
  15. Scully SP, Temple HT, Okeefe RJ, et al: Role of surgical resection in pelvic Ewing’s sarcoma. J Clin Oncol 13(9):2336–2341, 1995PubMedGoogle Scholar
  16. Simon MA, Bierman JS: Biopsy of bone and soft-tissue lesions. J Bone and Joint Surg 75A:616–621, 1993Google Scholar
  17. Sundaram M, McDonald DJ: Magnetic resonance imaging in the evaluation of the solitary tumor of bone. Current Opinion in Radiology 2:697–702, 1990PubMedGoogle Scholar
  18. Sundaram M, McDonald DJ: The solitary tumor or tumor-like lesion of bone. Top Magn Reson Imag 1(4): 17–29, 1989CrossRefGoogle Scholar
  19. Sundaram M, McGuire MH: Computed tomography or magnetic resonance for evaluating the solitary tumor or tumorlike lesion of bone? Skeletal Radiology 17:393–401, 1988PubMedCrossRefGoogle Scholar
  20. Ward WG, Mikaelian K, Dorey F, et al: Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 12(9):1849–1858, 1994PubMedGoogle Scholar
  21. Wei G, Antonescu CR, de Alva E, et al: Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 89:793–799, 2000PubMedCrossRefGoogle Scholar
  22. Wuisman P, Enneking WF: Prognosis for patients who have osteosarcoma with skip metastasis. J Bone and Joint Surg 72A(l):60–68, 1990Google Scholar
  23. Wunder JS, Bull SB, Aneliunas V, et al: MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 18:2685–2694, 2000PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • American Joint Committee on Cancer
    • 1
  1. 1.Executive OfficeChicagoUSA

Personalised recommendations